
  
    
      
        Background_NNP
        Mefloquine_NNP was_VBD developed_VBN by_IN the_DT US_NNP Army_NNP and_CC introduced_VBN
        for_IN the_DT treatment_NN of_IN malaria_NN in_IN the_DT late_JJ 1970_CD s_VBZ ._. [_NN 1_CD ]_NN
        Mefloquine_NNP was_VBD first_RB used_VBN for_IN prophylaxis_NNS in_IN 1985_CD ,_, and_CC
        since_IN then_RB approximately_RB 14_CD ._. 5_LS million_CD people_NNS have_VBP been_VBN
        prescribed_VBN the_DT drug_NN for_IN malaria_NN prevention_NN ,_, versus_CC 1_CD ._. 6_CD
        million_CD for_IN treatment_NN ._. [_NN 2_CD ]_NN
        In_IN the_DT first_JJ decade_NN of_IN mefloquine_NN 's_POS use_NN ,_, the_DT reported_VBD
        adverse_JJ effects_NNS were_VBD mainly_RB gastrointestinal_NN ._. [_NN 3_CD ]_NN In_IN the_DT
        late_JJ 1980_CD s_VBZ it_PRP became_VBD clear_JJ that_DT mefloquine_NN could_MD cause_VB
        neuropsychiatric_JJ adverse_JJ effects_NNS ._. [_NN 4_CD ]_NN The_DT first_JJ
        randomised_JJ controlled_VBN trial_NN of_IN mefloquine_NN prophylaxis_NNS in_IN
        heterogeneous_JJ ,_, non-immune_JJ Western_JJ travellers_NNS was_VBD published_VBN
        in_IN 2001_CD and_CC found_VBD that_DT one-third_NN of_IN all_DT mefloquine_NN users_NNS
        reported_VBD neuropsychiatric_JJ adverse_JJ effects_NNS and_CC 6_CD %_NN of_IN all_DT
        users_NNS reported_VBD at_IN least_JJS one_CD severe_JJ adverse_JJ event_NN (_( defined_VBN
        as_IN requiring_VBG medical_JJ advice_NN )_) ._. [_NN 5_CD ]_NN
        On_IN the_DT evidence_NN from_IN a_DT case_NN series_NN published_VBN in_IN 1992_CD by_IN
        the_DT manufacturer_NN ,_, Hoffmann-_NNP La_NNP Roche_NNP ,_, the_DT World_NNP Health_NNP
        Organisation_NNP (_( WHO_WP )_) recommends_VBZ that_IN travellers_NNS with_IN a_DT
        personal_NN or_CC family_NN history_NN of_IN seizures_NNS or_CC manic-depressive_NN
        illness_NN should_MD not_RB take_VB mefloquine_NN prophylaxis_NNS ._. [_NN 6_CD 7_CD ]_NN
        However_RB the_DT Centers_NNPS for_IN Disease_NNP Control_NNP and_CC their_PRP$ Canadian_JJ
        equivalent_NN ,_, CATMAT_NNP ,_, do_VBP not_RB recognise_NN this_DT as_IN a_DT valid_JJ
        contraindication_NN to_TO taking_VBG mefloquine_NN ._. [_NN 8_CD ]_NN
        A_DT recent_JJ analysis_NN of_IN spontaneous_JJ reports_NNS held_VBN on_IN the_DT
        Dutch_JJ national_JJ pharmacovigilance_NN database_NN suggested_VBD that_IN
        there_EX is_VBZ a_DT mefloquine_NN syndrome_NN consisting_VBG of_IN excessive_JJ
        sweating_NN accompanied_VBN by_IN malaise_NN ,_, nausea_NN ,_, diarrhoea_NN ,_,
        agitation_NN ,_, concentration_NN problems_NNS and_CC nightmares_NNS ._. [_NN 9_CD ]_NN
        The_DT aetiology_NN of_IN the_DT adverse_JJ effects_NNS associated_VBN with_IN
        mefloquine_NN use_NN remains_VBZ obscure_JJ ._. Ten_CD cohort_NN studies_NNS in_IN
        tourists_NNS found_VBD that_IN women_NNS generally_RB experienced_VBN worse_JJR side_NN
        effects_NNS from_IN mefloquine_NN than_IN men_NNS ;_: [_NN 6_CD 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD
        17_CD 18_CD ]_NN an_DT eleventh_NN did_VBD not_RB find_VB this_DT effect_NN ._. [_NN 19_CD ]_NN In_IN
        randomised_JJ controlled_VBN trials_NNS ,_, children_NNS have_VBP tolerated_JJ
        mefloquine_NN well_RB ._. [_NN 20_CD 21_CD ]_NN Surprisingly_RB ,_, one_CD cohort_NN study_NN
        found_VBD that_IN some_DT older_JJR adult_NN travellers_NNS tolerate_VB mefloquine_NN
        better_JJR than_IN younger_JJR adults_NNS ._. [_NN 22_CD ]_NN It_PRP has_VBZ also_RB been_VBN
        reported_VBN that_IN Asian_JJ patients_NNS tolerate_VB mefloquine_NN better_JJR
        than_IN Caucasians_NNP and_CC Africans_NNPS ._. [_NN 23_CD 24_CD ]_NN Despite_IN early_JJ
        concerns_NNS ,_, mefloquine_NN appears_VBZ to_TO be_VB safe_JJ in_IN pregnancy_NN ._. [_NN 25_CD
        ]_NN
        Although_IN the_DT adverse_JJ effects_NNS of_IN mefloquine_NN are_VBP common_JJ ,_,
        and_CC often_RB serious_JJ and_CC long_JJ lasting_JJ ,_, and_CC the_DT drug_NN has_VBZ been_VBN
        widely_RB used_VBN for_IN over_IN 20_CD years_NNS ,_, no_DT real_JJ attempts_NNS have_VBP so_RB far_RB
        been_VBN made_VBN to_TO investigate_VB and_CC explain_VB these_DT effects_NNS ._. A_DT
        systematic_JJ review_NN of_IN mefloquine_NN prophylaxis_NNS ,_, performed_VBN
        within_IN the_DT Cochrane_NNP Collaboration_NNP ,_, now_RB tabulates_NNS 516_CD case_NN
        reports_NNS published_VBN in_IN 136_CD papers_NNS between_IN 1976_CD -_: 2000_CD ,_,
        describing_VBG adverse_JJ effects_NNS from_IN mefloquine_NN at_IN prophylactic_JJ
        and_CC therapeutic_JJ dosages_NNS ._. [_NN 26_CD ]_NN
        We_PRP retrieved_VBD and_CC critically_RB reviewed_VBD all_PDT the_DT original_JJ
        papers_NNS listed_VBN in_IN the_DT Cochrane_NNP review_NN to_TO clarify_VB the_DT
        phenomenology_NN of_IN the_DT adverse_JJ effects_NNS associated_VBN with_IN
        mefloquine_NN ,_, and_CC to_TO look_VB for_IN clues_NNS to_TO possibly_RB safer_JJR use_NN of_IN
        the_DT drug_NN ._.
      
      
        Analysis_NNP of_IN case_NN reports_NNS
        
          Common_JJ features_NNS of_IN the_DT case_NN reports_NNS
          Of_IN the_DT 516_CD published_VBN case_NN reports_NNS of_IN mefloquine_NN
          adverse_JJ effects_NNS recorded_VBN in_IN the_DT mefloquine_NN systematic_JJ
          review_NN ,_, 328_CD of_IN the_DT reports_NNS related_VBN to_TO prophylactic_JJ
          mefloquine_NN use_NN ,_, and_CC 188_CD to_TO treatment_NN use_NN ._. 324_CD of_IN the_DT 516_CD
          cases_NNS (_( 63_CD %_NN )_) related_VBN to_TO tourists_NNS or_CC business_NN travellers_NNS ._. [_NN
          26_CD ]_NN One-third_NNP of_IN the_DT reports_NNS were_VBD in_IN languages_NNS other_JJ
          than_IN English_NNP -_: mainly_RB French_JJ ,_, German_JJ and_CC Danish_JJ ._. The_DT
          search_NN strategy_NN for_IN finding_VBG the_DT case_NN reports_NNS is_VBZ described_VBN
          in_IN the_DT review_NN ._. [_NN 26_CD ]_NN An_DT annotated_JJ bibliography_NN of_IN the_DT
          516_CD published_VBN reports_NNS can_MD be_VB found_VBN at_IN
          http_NN :_: /_NN /_NN www_NN ._. liv_NN ._. ac_NN ._. uk_NN /_NN evidence_NN ._.
          26_CD %_NN of_IN the_DT case_NN reports_NNS recorded_VBD three_CD or_CC fewer_RBR
          individual_JJ patient_NN parameters_NNS (_( for_IN example_NN ,_, the_DT patient_NN 's_POS
          age_NN ,_, sex_NN and_CC mefloquine_NN dose_NN taken_VBN )_) ,_, and_CC many_JJ of_IN these_DT
          reports_NNS were_VBD little_JJ more_JJR than_IN a_DT short_JJ description_NN of_IN an_DT
          unexpected_JJ adverse_JJ event_NN ,_, set_VBN in_IN the_DT context_NN of_IN a_DT larger_JJR
          study_NN ._. 52_CD %_NN of_IN the_DT reports_NNS however_RB contained_VBD some_DT
          discussion_NN of_IN the_DT causality_NN of_IN the_DT symptoms_NNS attributed_VBD to_TO
          the_DT drug_NN ,_, and_CC 11_CD %_NN proposed_VBD a_DT mechanism_NN by_IN which_WDT these_DT
          symptoms_NNS might_MD be_VB occurring_VBG ._.
          56_CD %_NN of_IN the_DT 516_CD case_NN reports_NNS we_PRP reviewed_VBD described_VBD one_CD
          or_CC more_JJR symptoms_NNS consistent_JJ with_IN a_DT 
          transient_JJ ,_, anicteric_JJ chemical_NN
          hepatitis_NN (_( eg_NN ,_, malaise_NN ,_, fever_NN ,_, anorexia_NN ,_, headache_NN ,_,
          abdominal_NN pain_NN ,_, nausea_NN ,_, diarrhoea_NN ,_, concentration_NN
          difficulties_NNS )_) ._. Of_IN the_DT remaining_VBG reports_NNS ,_, many_JJ were_VBD
          consistent_JJ with_IN a_DT 
          post-hepatic_JJ syndrome_NN ,_, although_IN in_IN
          some_DT cases_VBZ the_DT disorders_NNS described_VBD could_MD have_VB been_VBN due_JJ to_TO
          conditions_NNS such_JJ as_IN anxiety_NN ,_, depression_NN ,_, chronic_JJ fatigue_NN
          or_CC jet_NN lag_NN ._.
          15_CD %_NN of_IN all_PDT the_DT case_NN reports_NNS described_VBD symptomatology_NN
          suggesting_VBG acutely_RB 
          disturbed_VBN thyroid_NN function_NN (_( eg_NN ,_,
          anorexia_NN ,_, fatigue_NN ,_, tremor_NN ,_, palpitations_NNS ,_, nervousness_NN ,_,
          increased_VBN sweating_NN ,_, mood_NN and_CC /_NN or_CC sleep_VB disturbance_NN ,_, memory_NN
          and_CC concentration_NN disorders_NNS ,_, emotional_JJ lability_NN ,_, altered_VBN
          bowel_NN habit_NN ,_, depression_NN )_) ._.
          Table_NNP 1_CD categorises_NNS the_DT 516_CD published_VBN case_NN reports_NNS
          according_VBG to_TO whether_IN the_DT clinical_JJ features_VBZ were_VBD '_POS very_RB
          likely_JJ '_POS ,_, '_'' plausibly_RB '_POS or_CC probably_RB '_POS unrelated_JJ '_POS to_TO liver_NN or_CC
          thyroid_NN pathology_NN ._. We_PRP have_VBP based_VBN this_DT classification_NN on_IN
          standard_JJ lists_NNS of_IN the_DT common_JJ symptoms_NNS and_CC signs_NNS of_IN liver_NN
          and_CC thyroid_NN disease_NN ._. [_NN 27_CD 28_CD ]_NN The_DT direction_NN of_IN thyroid_NN
          symptoms_NNS was_VBD mainly_RB towards_IN hyperthyroidism_NN ,_, though_IN some_DT
          patients_NNS exhibited_VBN signs_NNS of_IN both_DT an_DT over-_NN and_CC an_DT
          under-active_JJ thyroid_NN (_( for_IN example_NN ,_, tachycardia_NN
          alternating_VBG with_IN bradycardia_NN )_) ._.
          The_DT table_NN also_RB shows_VBZ the_DT median_JJ duration_NN of_IN symptoms_NNS
          reported_VBN by_IN '_POS prophylactic_JJ '_POS and_CC '_POS treatment_NN '_'' mefloquine_NN
          users_NNS ,_, and_CC the_DT median_JJ dose_NN taken_VBN within_IN each_DT category_NN ._.
          The_DT median_JJ duration_NN of_IN adverse_JJ effects_NNS of_IN patients_NNS who_WP
          took_VBD mefloquine_NN as_IN treatment_NN appears_VBZ to_TO have_VB been_VBN shorter_JJR
          than_IN that_DT of_IN those_DT who_WP took_VBD the_DT drug_NN as_IN prophylaxis_NNS (_( 4_CD
          days_NNS versus_CC 16_CD days_NNS )_) ,_, even_RB though_IN the_DT median_JJ dose_NN of_IN
          mefloquine_NN taken_VBN was_VBD higher_JJR in_IN the_DT treatment_NN group_NN ._. We_PRP
          believe_VBP that_IN one_CD explanation_NN for_IN this_DT unexpected_JJ finding_NN
          may_MD lie_VB in_IN the_DT fact_NN that_IN the_DT treatment_NN users_NNS of_IN
          mefloquine_NN were_VBD more_RBR likely_JJ to_TO have_VB taken_VBN the_DT drug_NN as_IN
          monotherapy_NN ,_, whereas_IN the_DT prophylaxis_NNS users_NNS more_RBR commonly_RB
          took_VBD one_CD or_CC more_RBR co-medications_JJ ,_, as_RB well_RB as_IN alcohol_NN ._. We_PRP
          discuss_VBP the_DT possible_JJ significance_NN of_IN this_DT later_RB in_IN this_DT
          paper_NN ._.
        
        
          Mefloquine_NNP and_CC the_DT liver_NN
          Mefloquine_NNP is_VBZ an_DT aryl_NN amino_JJ alcohol_NN which_WDT accumulates_NNS
          in_IN both_DT the_DT liver_NN and_CC the_DT lungs_NNS ,_, and_CC is_VBZ subject_JJ to_TO
          enterohepatic_JJ circulation_NN ._. [_NN 29_CD ]_NN It_PRP has_VBZ recently_RB been_VBN
          found_VBN to_TO cause_VB acute_JJ hepatitis_NN ._. [_NN 30_CD ]_NN
          Mefloquine_NNP does_VBZ not_RB appear_VB to_TO cause_VB florid_NN signs_NNS of_IN
          liver_NN disease_NN ._. However_RB ,_, transient_JJ subclinical_JJ
          disturbances_NNS of_IN liver_NN function_NN are_VBP a_DT common_JJ feature_NN of_IN
          many_JJ drugs_NNS metabolised_JJ in_IN the_DT liver_NN ,_, and_CC this_DT may_MD explain_VB
          the_DT frequent_JJ finding_NN of_IN transaminase_NN changes_NNS in_IN safety_NN
          studies_NNS of_IN new_JJ drugs_NNS ;_: these_DT biochemical_JJ findings_NNS are_VBP
          usually_RB dismissed_VBN as_IN meaningless_JJ noise_NN ,_, but_CC they_PRP may_MD in_IN
          fact_NN be_VB sensitive_JJ or_CC oversensitive_JJ markers_NNS of_IN
          vulnerability_NN ,_, of_IN low_JJ specificity_NN ._.
          That_DT mefloquine_NN induces_VBZ liver_NN enzymes_NNS is_VBZ well_RB
          documented_VBN ._. Jaspers_NNP et_CC al_NN reported_VBD significantly_RB raised_VBN
          transaminases_NNS in_IN Dutch_JJ marines_NNS who_WP took_VBD mefloquine_NN during_IN
          3_CD months_NNS in_IN Cambodia_NNP ,_, and_CC who_WP were_VBD not_RB drinking_NN alcohol_NN
          at_IN the_DT time_NN ._. [_NN 31_CD ]_NN Takeshima_NNP found_VBD that_IN of_IN a_DT cohort_NN of_IN
          healthy_JJ Japanese_JJ soldiers_NNS who_WP took_VBD prophylactic_JJ
          mefloquine_NN for_IN 36_CD weeks_NNS without_IN drinking_NN alcohol_NN ,_,
          one-quarter_NN developed_VBD symptoms_NNS compatible_JJ with_IN liver_NN
          pathology_NN and_CC four_CD showed_VBD disturbed_VBN liver_NN function_NN ._. [_NN 32_CD
          ]_NN Reisinger_NNP et_CC al_NN observed_VBD the_DT same_JJ phenomenon_NN in_IN a_DT
          cohort_NN of_IN short-stay_JJ European_JJ travellers_NNS to_TO Africa_NNP ,_, but_CC
          it_PRP is_VBZ not_RB clear_JJ whether_IN alcohol_NN could_MD have_VB contributed_VBN to_TO
          this_DT effect_NN ._. [_NN 33_CD ]_NN One_CD of_IN the_DT travellers_NNS ,_, who_WP was_VBD
          concurrently_RB taking_VBG a_DT liver-damaging_JJ agent_NN ,_, sulfadoxine_NN ,_,
          [_NN 34_CD ]_NN showed_VBD gross_JJ morphological_JJ changes_NNS in_IN his_PRP$ liver_NN
          which_WDT were_VBD attributed_VBN to_TO his_PRP$ use_NN of_IN prophylactic_JJ
          mefloquine_NN ._. Liver_NNP biopsy_NN showed_VBD intralobular_NN cellular_JJ
          infiltrates_NNS consisting_VBG of_IN macrophages_NNS and_CC eosinophils_NNS as_RB
          well_RB as_IN sporadic_JJ eosinophilic_JJ cell_NN necroses_NNS ;_: virology_NN was_VBD
          negative_JJ ._. [_NN 33_CD ]_NN Grieco_NNP et_CC al_NN described_VBD a_DT 46_CD -_: year-old_JJ
          woman_NN who_WP drank_NN wine_NN daily_JJ while_IN taking_VBG mefloquine_NN ,_, and_CC
          who_WP became_VBD nervous_JJ and_CC depressed_VBN ,_, with_IN nausea_NN ,_, vomiting_NN
          and_CC diarrhoea_NN ._. She_PRP was_VBD dehydrated_JJ and_CC in_IN severe_JJ liver_NN
          failure_NN ,_, with_IN negative_JJ virology_NN ._. Liver_NNP biopsy_NN showed_VBD
          diffuse_NN macrovesical_JJ hepatic_JJ steatosis_NNS ._. [_NN 35_CD ]_NN
          '_POS Heavy_NNP sun_NN exposure_NN '_'' is_VBZ noted_VBN in_IN a_DT case_NN report_NN of_IN a_DT
          60_CD -_: year-old_JJ Frenchman_NNP who_WP reacted_VBD acutely_RB to_TO his_PRP$ second_JJ
          mefloquine_NN tablet_NN ;_: it_PRP is_VBZ likely_JJ that_IN this_DT sun_NN exposure_NN
          would_MD have_VB caused_VBN dehydration_NN ._. [_NN 5_CD ]_NN A_DT 20_CD -_: year_NN old_JJ French_JJ
          traveller_NN ,_, concurrently_RB taking_VBG an_DT oral_JJ contraceptive_NN ,_, had_VBD
          epileptic_JJ seizures_NNS in_IN her_PRP$ sixth_JJ week_NN of_IN mefloquine_NN
          prophylaxis_NNS ,_, directly_RB after_IN '_POS severe_JJ exertion_NN '_'' ._. [_NN 5_CD ]_NN It_PRP
          seems_VBZ likely_JJ that_IN in_IN some_DT mefloquine_NN users_NNS dehydration_NN
          will_MD impose_VB an_DT added_VBN burden_NN on_IN the_DT liver_NN ,_, and_CC that_IN this_DT
          could_MD contribute_VB to_TO a_DT severe_JJ reaction_NN to_TO the_DT drug_NN ._. Many_JJ
          long-haul_JJ travellers_NNS using_VBG mefloquine_NN are_VBP mildly_RB
          dehydrated_JJ from_IN in-flight_JJ alcohol_NN and_CC air_NN conditioning_NN ,_,
          followed_VBN by_IN hot_JJ and_CC dry_JJ conditions_NNS ,_, and_CC more_JJR alcohol_NN
          consumption_NN ,_, at_IN their_PRP$ holiday_NN or_CC business_NN
          destination_NN ._.
          Of_IN the_DT 516_CD case_NN reports_NNS we_PRP reviewed_VBD ,_, eleven_CD cited_VBD
          alcohol_NN as_RB possibly_RB contributing_VBG to_TO the_DT adverse_JJ drug_NN
          effects_NNS described_VBD ._. Wittes_NNP et_CC al_NN reported_VBD a_DT remarkable_JJ
          challenge-rechallenge_JJ experiment_NN where_WRB a_DT healthy_JJ male_JJ
          geologist_NN took_VBD both_DT his_PRP$ third_JJ and_CC his_PRP$ fourth_JJ weekly_JJ
          mefloquine_NN tablet_NN together_RB with_IN half_PDT a_DT bottle_NN of_IN whisky_NN ,_,
          and_CC on_IN both_DT occasions_NNS experienced_VBD acute_JJ paranoid_JJ
          delusions_NNS ,_, depression_NN and_CC suicidal_JJ ideation_NN ;_: a_DT fellow_NN
          geologist_NN who_WP shared_VBD the_DT same_JJ whisky_NN bottle_NN (_( and_CC who_WP was_VBD
          taking_VBG no_DT antimalaria_NN medication_NN )_) experienced_VBD no_DT such_JJ
          effects_NNS ._. [_NN 36_CD ]_NN
          Vuurman_NNP et_CC al_NN ,_, sponsored_VBN by_IN Hoffmann-_NNP La_NNP Roche_NNP ,_, tested_VBN
          in_IN healthy_JJ volunteers_NNS whether_IN or_CC not_RB alcohol_NN might_MD
          interact_NN adversely_RB with_IN mefloquine_NN ._. [_NN 37_CD ]_NN They_PRP found_VBD
          psychomotor_NN performance_NN unimpaired_JJ ,_, but_CC their_PRP$ study_NN
          design_NN had_VBD important_JJ limitations_NNS ._. Only_RB 20_CD participants_NNS
          took_VBD mefloquine_NN and_CC of_IN these_DT ,_, two_CD women_NNS dropped_VBD out_IN due_JJ
          to_TO adverse_JJ events_NNS (_( one_CD with_IN nausea_NN ,_, vomiting_NN and_CC
          dizziness_NN ,_, the_DT other_JJ with_IN malaise_NN ,_, fever_NN and_CC headache_NN )_) ._.
          The_DT study_NN protocol_NN forbade_VBD '_POS strenuous_JJ physical_JJ activity_NN '_''
          and_CC any_DT prescribed_VBN medications_NNS ._. Alcohol_NNP was_VBD given_VBN under_IN
          strict_JJ laboratory_NN conditions_NNS 24_CD h_NN after_IN mefloquine_NN
          ingestion_NN ,_, and_CC then_RB in_IN small_JJ and_CC interrupted_VBN doses_NNS ,_, such_JJ
          that_IN the_DT blood_NN alcohol_NN concentration_NN in_IN any_DT participant_NN
          never_RB exceeded_VBD 0_CD ._. 50_CD mg_NN ml_NN -_: 1_CD ._. The_DT authors_NNS admit_VBP that_IN
          their_PRP$ study_NN did_VBD not_RB address_VB '_POS the_DT question_NN of_IN what_WP might_MD
          happen_VB should_MD (_( mefloquine_NN users_NNS )_) consume_VBP intoxicating_VBG
          amounts_NNS of_IN alcohol_NN ._. [_NN 37_CD ]_NN Their_PRP$ findings_NNS can_MD thus_RB not_RB be_VB
          generalised_JJ to_TO the_DT broad_JJ population_NN of_IN tourists_NNS and_CC
          business_NN travellers_NNS ._.
          Approximately_RB half_NN of_IN the_DT case_NN reports_NNS listed_VBN in_IN the_DT
          Cochrane_NNP review_NN note_NN some_DT co-medication_JJ taken_VBN along_IN with_IN
          mefloquine_NN ._. [_NN 26_CD ]_NN Other_JJ quinoline_NN derivatives_NNS (_( chiefly_RB
          chloroquine_NN and_CC quinine_NN )_) are_VBP the_DT commonest_NN co-medications_JJ
          mentioned_VBN in_IN the_DT case_NN reports_NNS ._. After_IN antimalaria_NN drugs_NNS ,_,
          an_DT oral_JJ contraceptive_JJ (_( noted_VBD in_IN 8_CD reports_NNS )_) is_VBZ the_DT next_JJ
          most_RBS commonly_RB reported_VBD co-medication_JJ ,_, followed_VBN by_IN sodium_NN
          valproate_NN (_( 7_CD )_) and_CC diazepam_NN (_( 4_LS )_) ._. All_DT these_DT drugs_NNS can_MD cause_VB
          liver_NN damage_NN ._. [_NN 34_CD ]_NN Diazepam_NNP is_VBZ also_RB a_DT thyroid_NN hormone_NN
          antagonist_NN ,_, and_CC we_PRP discuss_VBP below_IN the_DT possible_JJ
          significance_NN of_IN this_DT ._. Meszaros_NNP et_CC al_NN reported_VBD a_DT male_JJ
          traveller_NN who_WP in_IN addition_NN to_TO mefloquine_NN took_VBD
          thioridazine_NN ,_, amitriptyline_NN and_CC fluphenazine_NN (_( all_DT capable_JJ
          of_IN damaging_VBG the_DT liver_NN )_) ,_, and_CC whose_WP$ mefloquine-associated_JJ
          neuropsychiatric_JJ symptoms_NNS persisted_VBD for_IN over_IN a_DT year_NN ._. [_NN 38_CD
          ]_NN Gullahorn_NNP et_CC al_NN reported_VBD a_DT series_NN of_IN patients_NNS who_WP
          experienced_VBD delirium_NN on_IN emerging_VBG from_IN anaesthesia_NN ,_,
          possibly_RB because_IN in_IN addition_NN to_TO mefloquine_NN they_PRP had_VBD
          received_VBN isoflurane_NN ,_, an_DT anaesthetic_JJ known_VBN to_TO cause_VB
          hepatocellular_NN necrosis_NNS ._. [_NN 34_CD 39_CD ]_NN
          One_CD report_NN describes_VBZ an_DT acute_JJ reaction_NN in_IN a_DT man_NN who_WP
          took_VBD one_CD mefloquine_NN tablet_NN each_DT week_NN together_RB with_IN two_CD
          aspirin_NN tablets_NNS ._. One_CD hour_NN after_IN taking_VBG his_PRP$ fifth_JJ
          mefloquine_NN tablet_NN he_PRP experienced_VBD acute_JJ amnesia_NN lasting_JJ
          approximately_RB one_CD hour_NN ._. [_NN 40_CD ]_NN Aspirin_NNP can_MD cause_VB
          hepatocellular_NN necrosis_NNS ,_, [_NN 34_CD ]_NN and_CC in_IN addition_NN can_MD
          aggravate_VB acute_JJ thyroid_NN disturbance_NN (_( discussed_VBN below_IN )_) by_IN
          competing_VBG with_IN thyroid_NN hormones_NNS for_IN sites_NNS on_IN binding_JJ
          proteins_NNS ._. [_NN 53_CD ]_NN
        
        
          Mefloquine_NNP and_CC the_DT thyroid_NN
          The_DT preclinical_JJ studies_NNS of_IN mefloquine_NN by_IN the_DT US_NNP Army_NNP
          involved_VBD close_VB monitoring_VBG in_IN animal_NN models_NNS and_CC human_JJ
          volunteers_NNS of_IN several_JJ organ_NN systems_NNS ,_, but_CC not_RB the_DT thyroid_NN ._.
          [_NN 1_CD ]_NN The_DT effect_NN of_IN mefloquine_NN on_IN thyroid_NN function_NN
          appears_VBZ not_RB to_TO have_VB been_VBN investigated_VBN in_IN any_DT phase_NN III_NNP or_CC
          phase_NN IV_NNP study_NN ._. Thyroid_NNP function_NN has_VBZ not_RB been_VBN tested_VBN
          routinely_RB in_IN the_DT diagnosis_NN or_CC management_NN of_IN patients_NNS
          suffering_VBG from_IN mefloquine-related_JJ adverse_JJ effects_NNS ._.
          Thyroid_NNP disease_NN ,_, or_CC some_DT possible_JJ interference_NN with_IN
          thyroid_NN activity_NN ,_, is_VBZ reported_VBN in_IN only_RB three_CD of_IN the_DT 516_CD
          case_NN reports_NNS in_IN the_DT Cochrane_NNP review_NN ._. [_NN 26_CD ]_NN Bem_NNP et_CC al_NN
          described_VBD a_DT 31_CD -_: year_NN old_JJ German_JJ woman_NN with_IN a_NNP '_POS thyroid_NN
          condition_NN '_'' ,_, who_WP was_VBD also_RB taking_VBG '_POS tranquillisers_NNS '_POS
          (_( unspecified_JJ )_) and_CC alcohol_NN ,_, and_CC who_WP had_VBD an_DT acute_JJ
          exacerbation_NN of_IN her_PRP$ schizophrenia_NN after_IN a_DT single_JJ tablet_NN
          of_IN mefloquine_NN ;_: her_PRP$ symptoms_NNS persisted_VBD for_IN 4_CD weeks_NNS ._. [_NN 5_CD ]_NN
          Conget_NNP et_CC al_NN reported_VBD a_DT 30_CD -_: year_NN old_JJ previously_RB healthy_JJ
          woman_NN who_WP experienced_VBD abdominal_NN pain_NN ,_, palpitations_NNS ,_,
          instability_NN ,_, insomnia_NN and_CC a_DT fine_NN distal_NN tremor_NN in_IN her_PRP$
          second_JJ week_NN of_IN mefloquine_NN prophylaxis_NNS ._. A_DT thyroid_NN function_NN
          screen_NN showed_VBD a_DT raised_VBN serum_NN thyroglobulin_NN level_NN (_( 54_CD

          μg_NN /_NN ml_NN ,_, normal_JJ range_NN 18_CD ._. 7_CD to_TO 27_CD ._. 1_LS )_) ;_: this_DT returned_VBD to_TO
          normal_JJ within_IN a_DT month_NN of_IN her_PRP$ stopping_VBG mefloquine_NN ._. [_NN 41_CD ]_NN
          Bauer_NNP et_CC al_NN reported_VBD acute_JJ psychotic_JJ reactions_NNS in_IN a_DT
          healthy_JJ US_NNP Peace_NNP Corps_NNP worker_NN who_WP took_VBD prophylactic_JJ
          mefloquine_NN concurrently_RB with_IN diiodohydroxyquinoline_NN for_IN a_DT
          presumed_VBN parasitic_JJ infection_NN ._. [_NN 42_CD ]_NN
        
      
      
        Presentation_NNP of_IN the_DT hypothesis_NNS
        
          The_DT mefloquine_NN syndrome_NN
          The_DT published_VBN literature_NN describes_VBZ a_DT mefloquine_NN
          syndrome_NN that_WDT presents_VBZ in_IN a_DT variety_NN of_IN ways_NNS including_VBG
          headache_NN ,_, gastrointestinal_NN disturbances_NNS ,_, nervousness_NN ,_,
          fatigue_NN ,_, disorders_NNS of_IN sleep_NN ,_, mood_NN ,_, memory_NN and_CC
          concentration_NN ,_, and_CC occasionally_RB frank_JJ psychosis_NNS ._. Young_NNP
          western_JJ women_NNS are_VBP particularly_RB vulnerable_JJ to_TO mefloquine_NN 's_POS
          adverse_JJ effects_NNS ._. Certain_JJ groups_NNS however_RB (_( children_NNS ,_, older_JJR
          adult_NN travellers_NNS and_CC Asian_JJ patients_NNS )_) tolerate_VB mefloquine_NN
          well_RB ._.
        
        
          Hypothesis_NNP
          The_DT phenomenology_NN of_IN mefloquine_NN 's_POS adverse_JJ effect_NN
          profile_NN ,_, together_RB with_IN incidental_JJ details_NNS in_IN some_DT of_IN the_DT
          published_VBN case_NN reports_NNS (_( references_NNS to_TO alcohol_NN ,_, and_CC to_TO
          known_VBN hepatotoxic_JJ co-medications_JJ such_JJ as_IN the_DT oral_JJ
          contraceptive_JJ pill_NN )_) suggest_VBP that_IN for_IN many_JJ mefloquine_NN
          users_NNS adverse_JJ drug_NN effects_NNS may_MD be_VB the_DT result_NN of_IN primary_JJ
          hepatocellular_NN injury_NN ,_, caused_VBN by_IN the_DT drug_NN in_IN association_NN
          with_IN one_CD or_CC more_RBR concurrent_JJ liver_NN insults_NNS ._. Further_RB ,_, it_PRP
          seems_VBZ that_IN in_IN some_DT of_IN these_DT symptomatic_JJ users_NNS of_IN
          mefloquine_NN a_DT transient_JJ thyroid_NN disturbance_NN may_MD appear_VB as_IN
          well_RB ,_, either_CC as_IN an_DT endocrine_NN disorder_NN secondary_JJ to_TO the_DT
          primary_JJ liver_NN damage_NN ,_, or_CC as_IN an_DT independent_JJ pathological_JJ
          process_NN ._.
          We_PRP therefore_RB postulate_NN that_IN many_JJ of_IN the_DT adverse_JJ
          effects_NNS of_IN mefloquine_NN are_VBP a_DT post-hepatic_JJ syndrome_NN caused_VBN
          by_IN primary_JJ liver_NN damage_NN ._. In_IN some_DT individuals_NNS we_PRP believe_VBP
          that_IN symptomatic_JJ thyroid_NN disturbance_NN occurs_VBZ ,_, either_CC as_IN an_DT
          independent_JJ process_NN ,_, or_CC as_IN a_DT secondary_JJ consequence_NN of_IN the_DT
          initial_JJ hepatocellular_NN injury_NN ._.
          Previous_JJ liver_NN or_CC thyroid_NN disease_NN ,_, and_CC concurrent_JJ
          insults_NNS to_TO the_DT liver_NN (_( such_JJ as_IN from_IN alcohol_NN ,_, dehydration_NN ,_,
          an_DT oral_JJ contraceptive_JJ pill_NN ,_, recreational_JJ drugs_NNS ,_, and_CC other_JJ
          drugs_NNS that_WDT can_MD damage_VB the_DT liver_NN )_) may_MD be_VB related_VBN to_TO the_DT
          development_NN of_IN many_JJ severe_JJ or_CC prolonged_JJ adverse_JJ reactions_NNS
          to_TO mefloquine_NN ._. Co-medications_NNP that_WDT are_VBP thyroid_NN hormone_NN
          antagonists_NNS may_MD also_RB be_VB risk_NN factors_NNS ._.
        
        
          Relevant_NNP reports_NNS with_IN other_JJ quinoline_NN
          derivatives_NNS
          Mefloquine_NNP is_VBZ a_DT synthetic_JJ quinoline_NN ;_: other_JJ quinolines_NNS
          include_VBP primaquine_NN ,_, amodiaquine_NN and_CC chloroquine_NN ._. [_NN 43_CD
          ]_NN
          High_JJ doses_NNS of_IN primaquine_NN in_IN rhesus_JJ monkeys_NNS have_VBP caused_VBN
          acute_JJ fatal_JJ liver_NN damage_NN ._. [_NN 44_CD ]_NN
          Amodiaquine_NNP is_VBZ still_RB used_VBN to_TO treat_VB malaria_NN ,_, but_CC was_VBD
          withdrawn_VBN from_IN general_JJ use_NN for_IN malaria_NN prophylaxis_NNS in_IN
          1986_CD after_IN it_PRP was_VBD found_VBN to_TO cause_VB liver_NN damage_NN and_CC
          hepatitis_NN ,_, mostly_RB anicteric_JJ ._. [_NN 45_CD 50_CD ]_NN Some_DT of_IN these_DT
          reports_NNS mention_VBP co-medications_JJ known_VBN to_TO damage_VB liver_NN
          cells_NNS (_( phenylbutazone_NN ,_, oral_JJ contraceptive_NN ,_, alcohol_NN )_) ._. [_NN 45_CD
          46_CD ]_NN Amodiaquine_NNP has_VBZ not_RB been_VBN linked_VBN to_TO disturbed_VBN thyroid_NN
          function_NN ._.
          The_DT possibility_NN of_IN a_DT three-way_JJ interaction_NN has_VBZ already_RB
          been_VBN suggested_VBN between_IN a_DT quinoline_NN derivative_JJ
          (_( chloroquine_NN )_) and_CC the_DT liver_NN and_CC the_DT thyroid_NN ._. Munera_NNP et_CC al_NN
          described_VBD a_DT woman_NN with_IN hypothyroidism_NN ,_, well_RB stabilised_JJ on_IN
          thyroxine_NN sodium_NN 125_CD μg_NN daily_JJ ,_, who_WP took_VBD prophylactic_JJ
          chloroquine_NN and_CC proguanil_NN daily_JJ for_IN 2_CD months_NNS for_IN a_DT
          vacation_NN in_IN Africa_NNP ._. [_NN 51_CD ]_NN At_IN four_CD weeks_NNS her_PRP$ thyroid_NN
          stimulating_VBG hormone_NN (_( TSH_NNP )_) concentration_NN was_VBD found_VBN to_TO be_VB
          very_RB high_JJ (_( 44_CD ._. 8_CD mU_NN /_NN 1_CD ,_, normal_JJ range_NN 0_CD ._. 35_CD -_: 6_CD ._. 0_CD )_) ,_, but_CC it_PRP
          returned_VBD to_TO normal_JJ within_IN a_DT week_NN of_IN her_PRP$ stopping_VBG the_DT
          drugs_NNS ._. Re-challenge_NNP with_IN chloroquine_NN and_CC proguanil_NN a_DT year_NN
          later_RB again_RB resulted_VBD in_IN raised_VBD levels_NNS of_IN TSH_NNP ,_, a_DT lowered_VBN
          concentration_NN of_IN free_JJ triiodothyronine_NN (_( T_NN 
          3_LS )_) ,_, and_CC normal_JJ free_JJ thyroxine_NN (_( T_NN 
          4_LS )_) concentration_NN ._. Liver_NNP function_NN was_VBD
          not_RB tested_VBN ,_, but_CC the_DT authors_NNS speculated_VBD that_DT
          '_POS Chloroquine_NNP ._. ._. ._. seems_VBZ to_TO have_VB enhanced_VBN the_DT induction_NN of_IN
          liver_NN enzymes_NNS ._. [_NN It_PRP ]_NN probably_RB increased_VBD the_DT catabolism_NN of_IN
          thyroid_NN hormones_NNS by_IN enzymatic_JJ induction_NN ._. [_NN 51_CD ]_NN They_PRP also_RB
          suggested_VBD that_DT chloroquine_NN might_MD act_VB centrally_RB on_IN the_DT
          hypothalamus_JJ ,_, through_IN disruption_NN of_IN the_DT feedback_NN system_NN
          by_IN which_WDT thyrotropin_NN releasing_VBG hormone_NN stimulates_NNS the_DT
          pituitary_JJ to_TO release_VB and_CC later_RB synthesise_NN TSH_NNP ._. [_NN 52_CD ]_NN
          A_DT third_JJ mechanism_NN by_IN which_WDT chloroquine_NN and_CC chemically_RB
          related_VBN drugs_NNS such_JJ as_IN mefloquine_NN might_MD interfere_VB with_IN
          thyroid_NN function_NN is_VBZ through_IN structural_JJ homology_NN to_TO T_NN 
          3_CD ,_, resulting_VBG in_IN thyroid_NN hormone_NN
          antagonism_NN ._. [_NN 53_CD ]_NN In_IN the_DT rat_NN ,_, chloroquine_NN injections_NNS
          more_JJR than_IN halve_VB the_DT T_NN 
          3_CD concentration_NN ,_, without_IN changing_VBG the_DT
          level_NN of_IN free_JJ T_NN 
          4_CD ._. [_NN 54_CD ]_NN Chloroquine_NNP has_VBZ been_VBN
          reported_VBN to_TO inhibit_VB T_NN 
          3_CD uptake_NN in_IN mammalian_JJ cells_NNS by_IN
          inhibiting_VBG receptor-mediated_JJ endocytosis_NNS ._. [_NN 53_CD ]_NN
        
      
      
        Testing_NNP the_DT hypothesis_NNS
        Our_PRP$ hypothesis_NNS needs_VBZ to_TO be_VB tested_VBN through_IN a_DT large_JJ
        multicentre_NN cohort_NN study_NN of_IN mefloquine_NN prophylaxis_NNS in_IN
        tourists_NNS and_CC business_NN travellers_NNS ,_, perhaps_RB recruited_VBN in_IN
        collaboration_NN with_IN one_CD or_CC more_JJR airlines_NNS ._. Small_JJ randomised_JJ
        controlled_VBN trials_NNS should_MD test_VB specific_JJ elements_NNS of_IN the_DT
        hypothesis_NNS ,_, such_JJ as_IN the_DT postulated_JJ link_NN between_IN mefloquine_NN
        and_CC thyroid_NN disturbance_NN ,_, and_CC the_DT presumed_VBN interaction_NN
        between_IN mefloquine_NN and_CC oral_JJ contraception_NN ._. National_JJ
        pharmacovigilance_NN databases_NNS should_MD also_RB be_VB analysed_JJ
        systematically_RB to_TO see_VB if_IN the_DT spontaneous_JJ reports_NNS of_IN
        mefloquine_NN 's_POS adverse_JJ effects_NNS tend_VBP to_TO support_VB our_PRP$ hypothesis_NNS
        or_CC not_RB ._.
        The_DT multicentre_NN cohort_NN study_NN of_IN prophylactic_JJ mefloquine_NN
        use_NN should_MD be_VB questionnaire-based_JJ ,_, and_CC should_MD enquire_NN
        specifically_RB into_IN the_DT major_JJ risk_NN factors_NNS (_( alcohol_NN intake_NN
        during_IN travel_NN ,_, hydration_NN status_NN ,_, use_NN of_IN hormonal_NN
        contraception_NN and_CC recreational_JJ drugs_NNS ,_, other_JJ potentially_RB
        hepatotoxic_JJ or_CC thyrotoxic_JJ drugs_NNS ,_, previous_JJ history_NN of_IN proven_VBN
        or_CC suspected_VBN liver_NN and_CC /_NN or_CC thyroid_NN abnormality_NN )_) that_IN we_PRP have_VBP
        proposed_VBN ._. The_DT study_NN design_NN should_MD include_VB pre-_NN and_CC
        post-exposure_JJ testing_NN of_IN liver_NN and_CC thyroid_NN function_NN in_IN at_IN
        least_JJS a_DT sample_NN of_IN the_DT cohort_NN ._.
        One_CD or_CC more_RBR case-control_JJ studies_NNS should_MD be_VB nested_JJ within_IN
        the_DT cohort_NN study_NN ._. [_NN 55_CD 56_CD ]_NN These_DT nested_JJ studies_NNS would_MD
        allow_VB for_IN rigorous_JJ testing_NN of_IN the_DT aetiological_JJ mechanisms_NNS
        which_WDT we_PRP have_VBP proposed_VBN for_IN mefloquine_NN 's_POS adverse_JJ effects_NNS ._.
        The_DT studies_NNS should_MD also_RB resolve_VB those_DT prescribing_VBG issues_NNS on_IN
        which_WDT experts_NNS '_POS opinions_NNS differ_VBP (_( eg_NN ,_, Is_VBZ mefloquine_NN safe_JJ in_IN
        pregnancy_NN ?_. Is_VBZ it_PRP safe_JJ for_IN long-term_JJ prophylaxis_NNS ?_. Should_MD
        airline_NN pilots_NNS be_VB prescribed_VBN mefloquine_NN ?_. Should_MD mefloquine_NN
        be_VB prescribed_VBN to_TO people_NNS with_IN a_DT personal_NN or_CC family_NN history_NN
        of_IN neuropsychiatric_JJ illness_NN ?_. Can_MD mefloquine_NN be_VB given_VBN safely_RB
        as_IN a_DT pre-travel_JJ loading_NN dose_NN ,_, for_IN rapid_JJ induction_NN of_IN
        chemoprophylaxis_NNS ?_. [_NN 17_CD 57_CD ]_NN )_) ._.
        Mefloquine_NNP is_VBZ a_DT clinically_RB important_JJ drug_NN ,_, commonly_RB used_VBN
        by_IN healthy_JJ people_NNS ._. A_DT much_RB higher_JJR standard_NN of_IN safety_NN is_VBZ
        therefore_RB required_VBN for_IN mefloquine_NN prophylaxis_NNS than_IN for_IN
        drugs_NNS given_VBN to_TO treat_VB serious_JJ diseases_NNS ._. [_NN 58_CD 59_CD ]_NN The_DT study_NN
        we_PRP propose_VBP is_VBZ urgently_RB needed_VBN ._.
      
      
        Implications_NNP of_IN the_DT hypothesis_NNS
        
          What_WP our_PRP$ hypothesis_NNS explains_VBZ
          The_DT hypothesis_NNS explains_VBZ much_JJ of_IN the_DT complexity_NN of_IN the_DT
          pattern_NN of_IN adverse_JJ effects_NNS of_IN mefloquine_NN ,_, and_CC also_RB the_DT
          fact_NN that_IN many_JJ healthy_JJ users_NNS of_IN the_DT drug_NN suffer_VBP no_DT
          adverse_JJ effects_NNS at_IN all_DT ._. It_PRP also_RB explains_VBZ some_DT aspects_NNS of_IN
          mefloquine_NN 's_POS tolerability_NN profile_NN in_IN travellers_NNS which_WDT
          until_IN now_RB have_VBP not_RB been_VBN understood_VBN ,_, notably_RB that_IN young_JJ
          women_NNS experience_VBP more_RBR adverse_JJ effects_NNS from_IN mefloquine_NN
          than_IN men_NNS ,_, and_CC that_IN children_NNS and_CC older_JJR adult_NN travellers_NNS
          (_( who_WP do_VBP not_RB use_VB oral_JJ contraception_NN ,_, and_CC who_WP rarely_RB misuse_NN
          alcohol_NN )_) seem_VBP to_TO tolerate_VB the_DT drug_NN well_RB ._. In_IN addition_NN ,_, our_PRP$
          hypothesis_NNS may_MD explain_VB the_DT ethnic_JJ and_CC inter_NN individual_JJ
          variations_NNS in_IN the_DT pharmacokinetics_NNS of_IN this_DT agent_NN ,_, which_WDT
          until_IN now_RB have_VBP not_RB been_VBN understood_VBN ._. [_NN 23_CD 24_CD ]_NN
          It_PRP has_VBZ been_VBN known_VBN for_IN some_DT years_NNS that_WDT mefloquine_NN users_NNS
          who_WP take_VBP co-medications_JJ are_VBP about_IN 1_CD ._. 5_CD times_NNS more_RBR likely_JJ
          to_TO experience_VB an_DT adverse_JJ drug_NN event_NN than_IN those_DT users_NNS who_WP
          take_VBP no_DT co-medications_JJ ,_, and_CC twice_RB as_IN likely_JJ to_TO experience_VB
          severe_JJ adverse_JJ drug_NN events_NNS ._. [_NN 14_CD ]_NN The_DT frequency_NN of_IN
          reported_VBD adverse_JJ drug_NN events_NNS also_RB increases_VBZ when_WRB multiple_JJ
          co-medications_JJ are_VBP taken_VBN ._. [_NN 14_CD ]_NN Our_PRP$ hypothesis_NNS plausibly_RB
          explains_VBZ these_DT earlier_JJR findings_NNS ._.
          The_DT use_NN of_IN marijuana_NN and_CC other_JJ psychoactive_JJ agents_NNS by_IN
          chloroquine_NN users_NNS has_VBZ been_VBN associated_VBN with_IN acute_JJ
          psychotic_JJ reactions_NNS ,_, and_CC it_PRP has_VBZ been_VBN suggested_VBN that_IN
          mefloquine_NN users_NNS who_WP take_VBP recreational_JJ drugs_NNS may_MD likewise_RB
          be_VB predisposed_JJ to_TO neuropsychiatric_JJ problems_NNS ._. [_NN 60_CD 61_CD ]_NN We_PRP
          believe_VBP that_IN this_DT association_NN is_VBZ consistent_JJ with_IN our_PRP$
          hypothesis_NNS ,_, since_IN recreational_JJ drugs_NNS can_MD cause_VB
          hepatocellular_NN damage_NN and_CC liver_NN failure_NN ._. [_NN 34_CD ]_NN
          A_DT puzzling_JJ observation_NN is_VBZ that_IN although_IN the_DT adverse_JJ
          effects_NNS of_IN mefloquine_NN are_VBP usually_RB reversible_JJ ,_, in_IN some_DT
          patients_NNS these_DT effects_NNS can_MD persist_VB for_IN months_NNS or_CC even_RB
          years_NNS after_IN the_DT drug_NN has_VBZ been_VBN stopped_VBN ._. [_NN 61_CD ]_NN We_PRP believe_VBP
          that_IN the_DT occasionally_RB protracted_JJ time_NN course_NN of_IN the_DT
          adverse_JJ effects_NNS can_MD be_VB plausibly_RB explained_VBN by_IN supposing_VBG
          that_IN in_IN these_DT patients_NNS mefloquine_NN is_VBZ just_RB one_CD of_IN several_JJ
          concurrent_JJ insults_NNS to_TO the_DT liver_NN ,_, and_CC that_IN it_PRP is_VBZ the_DT
          continuance_NN of_IN the_DT other_JJ insults_NNS (_( most_RBS commonly_RB alcohol_NN ,_,
          and_CC certain_JJ prescription_NN drugs_NNS )_) that_WDT makes_VBZ the_DT
          mefloquine-induced_JJ syndrome_NN persist_VB ._. Some_DT published_VBN
          evidence_NN supports_VBZ this_DT view_NN ._. [_NN 38_CD 62_CD 69_CD ]_NN There_EX is_VBZ
          evidence_NN from_IN this_DT study_NN (_( Table_NNP 1_LS )_) that_IN the_DT adverse_JJ
          effects_NNS of_IN mefloquine_NN in_IN those_DT who_WP have_VBP taken_VBN the_DT drug_NN
          prophylactically_RB persist_VB longer_RBR than_IN they_PRP do_VBP in_IN patients_NNS
          who_WP have_VBP been_VBN treated_VBN with_IN it_PRP ,_, even_RB though_IN the_DT latter_JJ
          group_NN mostly_RB receive_VB larger_JJR doses_NNS of_IN the_DT drug_NN ;_: this_DT
          paradox_NN might_MD be_VB explained_VBN by_IN the_DT fact_NN that_IN although_IN
          prophylactic_JJ users_NNS usually_RB stop_VBP mefloquine_NN as_RB soon_RB as_IN
          they_PRP have_VBP experienced_VBN adverse_JJ effects_NNS ,_, they_PRP often_RB
          continue_VBP to_TO assault_NN their_PRP$ livers_NNS in_IN other_JJ ways_NNS ,_, and_CC it_PRP is_VBZ
          this_DT which_WDT makes_VBZ the_DT effects_NNS persist_VBP ._.
          Most_JJS of_IN the_DT reported_VBN adverse_JJ effects_NNS of_IN mefloquine_NN fit_NN
          into_IN the_DT model_NN we_PRP propose_VBP ._. For_IN example_NN ,_, mefloquine_NN has_VBZ
          been_VBN associated_VBN with_IN a_DT wide_JJ variety_NN of_IN dermatological_JJ
          adverse_JJ effects_NNS ,_, and_CC most_JJS of_IN these_DT can_MD be_VB linked_VBN with_IN
          effects_NNS on_IN the_DT liver_NN or_CC thyroid_NN ._. [_NN 41_CD 55_CD ]_NN Convulsions_NNP
          and_CC dizziness_NN are_VBP other_JJ reported_VBN effects_NNS of_IN mefloquine_NN
          which_WDT can_MD be_VB related_VBN to_TO liver_NN or_CC thyroid_NN disturbance_NN ._. [_NN 2_CD
          41_CD ]_NN
        
        
          Who_WP should_MD not_RB take_VB mefloquine_NN ?_.
          We_PRP believe_VBP that_IN people_NNS with_IN a_DT history_NN of_IN any_DT proven_VBN or_CC
          suspected_VBN liver_NN or_CC thyroid_NN abnormality_NN in_IN the_DT previous_JJ
          two_CD years_NNS should_MD avoid_VB mefloquine_NN ._. Travellers_NNP taking_VBG
          mefloquine_NN should_MD not_RB drink_VB alcohol_NN ,_, especially_RB within_IN 24_CD
          h_NN of_IN their_PRP$ weekly_JJ mefloquine_NN dose_NN ._.
          While_IN taking_VBG mefloquine_NN ,_, travellers_NNS should_MD be_VB advised_VBN
          to_TO maintain_VB good_JJ hydration_NN with_IN water_NN or_CC carbonated_JJ
          drinks_NNS ,_, especially_RB on_IN long_JJ plane_NN journeys_NNS or_CC during_IN
          arduous_JJ work_NN in_IN hot_JJ conditions_NNS ._. Alcohol_NNP ,_, tea_NN or_CC coffee_NN
          should_MD not_RB be_VB used_VBN to_TO maintain_VB hydration_NN ,_, since_IN they_PRP all_DT
          increase_NN water_NN loss_NN ._.
          Travellers_NNP taking_VBG mefloquine_NN should_MD not_RB take_VB a_DT
          hormonal_NN contraceptive_JJ ,_, nor_CC any_DT other_JJ drug_NN known_VBN to_TO
          injure_VB liver_NN cells_NNS ._. [_NN 34_CD ]_NN They_PRP should_MD not_RB take_VB any_DT drug_NN
          known_VBN to_TO antagonise_NN thyroid_NN hormone_NN ._. [_NN 53_CD ]_NN We_PRP propose_VBP
          that_IN drugs_NNS that_WDT are_VBP known_VBN to_TO cause_VB hepatocellular_NN injury_NN 
          and_CC also_RB to_TO be_VB thyroid_NN hormone_NN
          antagonists_NNS should_MD be_VB absolutely_RB contraindicated_JJ in_IN
          mefloquine_NN users_NNS ;_: such_JJ drugs_NNS include_VBP amiodarone_NN ,_,
          benzodiazepines_NNS ,_, calcium_NN channel_NN blockers_NNS and_CC phenytoin_NN ._.
          [_NN 34_CD 53_CD ]_NN
          Because_IN of_IN the_DT potential_NN for_IN additive_JJ toxicity_NN ,_,
          travellers_NNS taking_VBG mefloquine_NN should_MD avoid_VB concurrent_JJ use_NN
          of_IN any_DT other_JJ quinoline_NN derivative_JJ (_( eg_NN ,_, amodiaquine_NN ,_,
          chloroquine_NN ,_, primaquine_NN ,_, quinidine_NN ,_, quinine_NN ,_,
          tafenoquine_NN )_) ,_, whether_IN for_IN additional_JJ prophylaxis_NNS or_CC for_IN
          treatment_NN ._. The_DT administration_NN of_IN a_DT different_JJ quinoline_NN
          derivative_JJ at_IN the_DT same_JJ time_NN as_IN mefloquine_NN may_MD increase_VB
          the_DT risk_NN of_IN adverse_JJ effects_NNS ._. [_NN 70_CD 72_CD ]_NN For_IN the_DT same_JJ
          reason_NN ,_, mefloquine_NN users_NNS should_MD avoid_VB other_JJ quinine_NN
          analogues_NNS ,_, such_JJ as_IN fluoroquinolone_NN antibiotics_NNS ._.
          Fluoroquinolones_NNP ,_, such_JJ as_IN sparfloxacin_NN ,_, of_IN loxacin_NN and_CC
          ciprofloxacin_NN ,_, are_VBP increasingly_RB prescribed_VBN in_IN severe_JJ
          cases_NNS of_IN traveller_NN 's_POS diarrhoea_NN ,_, and_CC have_VBP been_VBN associated_VBN
          with_IN severe_JJ reactions_NNS in_IN mefloquine_NN users_NNS ._. [_NN 73_CD ]_NN
        
        
          Who_WP should_MD take_VB mefloquine_NN ?_.
          Mefloquine_NNP is_VBZ a_DT safe_JJ and_CC exceptionally_RB useful_JJ drug_NN for_IN
          the_DT mass_NN prophylaxis_NNS and_CC treatment_NN of_IN those_DT resident_NN
          populations_NNS in_IN malaria-endemic_JJ areas_NNS which_WDT traditionally_RB
          abstain_NN from_IN alcohol_NN and_CC hormonal_NN contraception_NN ._. It_PRP has_VBZ
          been_VBN suggested_VBN that_IN in_IN such_JJ settings_NNS ,_, mefloquine_NN should_MD
          be_VB combined_VBN with_IN artemisinin_NN or_CC a_DT derivative_NN to_TO protect_VB
          both_DT drugs_NNS from_IN resistance_NN ._. [_NN 74_CD ]_NN
          On_IN the_DT basis_NN of_IN our_PRP$ hypothesis_NNS ,_, we_PRP believe_VBP that_IN
          children_NNS ,_, and_CC also_RB pregnant_JJ women_NNS ,_, can_MD safely_RB be_VB
          prescribed_VBN mefloquine_NN (_( because_IN neither_DT group_NN uses_VBZ alcohol_NN
          or_CC oral_JJ contraceptives_NNS )_) ._.
          Accompanied_NNP by_IN explicit_JJ advice_NN to_TO avoid_VB alcohol_NN ,_,
          maintain_VB good_JJ hydration_NN ,_, and_CC use_VB co-medications_JJ with_IN
          caution_NN ,_, we_PRP believe_VBP that_IN prophylactic_JJ mefloquine_NN could_MD be_VB
          recommended_VBN to_TO certain_JJ occupational_NN subsets_NNS of_IN travellers_NNS
          who_WP carry_VBP out_IN safety-critical_JJ tasks_NNS and_CC who_WP until_IN now_RB
          have_VBP been_VBN denied_VBN the_DT use_NN of_IN this_DT drug_NN ._. These_DT occupational_NN
          groups_NNS include_VBP airline_NN pilots_NNS ,_, [_NN 75_CD ]_NN divers_NNS [_NN 76_CD ]_NN and_CC
          operators_NNS of_IN heavy_JJ machinery_NN ._. [_NN 77_CD ]_NN
          Some_DT authorities_NNS advise_VBP that_IN travellers_NNS engaged_VBN in_IN
          high-risk_JJ leisure_NN pursuits_NNS ,_, such_JJ as_IN mountain_NN climbing_VBG ,_,
          should_MD not_RB use_VB mefloquine_NN ._. [_NN 78_CD ]_NN We_PRP believe_VBP that_IN this_DT
          exclusion_NN is_VBZ unjustified_JJ ,_, as_RB long_RB as_IN there_EX is_VBZ no_DT recent_JJ
          history_NN of_IN liver_NN or_CC thyroid_NN disease_NN ,_, and_CC provided_VBD the_DT
          precautions_NNS we_PRP have_VBP proposed_VBN above_IN (_( avoidance_NN of_IN alcohol_NN ,_,
          maintenance_NN of_IN hydration_NN and_CC non-use_JJ of_IN hormonal_NN
          contraception_NN ,_, recreational_JJ drugs_NNS and_CC certain_JJ
          co-medications_JJ )_) are_VBP adhered_VBD to_TO ._.
          Lobel_NNP et_CC al_NN consider_VB that_IN WHO_WP 's_VBZ exclusion_NN of_IN people_NNS
          with_IN a_DT personal_NN or_CC family_NN history_NN of_IN neuropsychiatric_JJ
          illness_NN from_IN taking_VBG mefloquine_NN is_VBZ based_VBN '_POS on_IN limited_JJ
          evidence_NN or_CC theoretical_JJ concerns_NNS '_POS ,_, and_CC we_PRP believe_VBP their_PRP$
          scepticism_NN is_VBZ justified_JJ ._. [_NN 79_CD ]_NN Neuropsychiatric_NNP illness_NN
          may_MD not_RB contraindicate_NN use_NN of_IN mefloquine_NN ,_, provided_VBN that_IN
          the_DT patient_NN is_VBZ not_RB currently_RB taking_VBG anything_NN that_WDT can_MD
          cause_VB liver_NN damage_NN or_CC thyroid_NN disturbance_NN ._.
        
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
